Frequently Asked Questions
The DecisionDx-SCC test sample is taken from your original biopsy or surgery, so there is no need for another procedure. Once completed, test results are sent directly to your healthcare provider.
The DecisionDx-SCC test result provides a genomic-based determination of your tumor’s likelihood to metastasize within the next 3 years. The test classifies Class 1 (low), Class 2A (moderate), and Class 2B (high) biological risk of metastasis. Most patients have low or moderate biological risk.
Having an accurate understanding of the risk of your cancer metastasizing (spreading) is a critical part of determining the right approach to your treatment and ongoing management of SCC. Similar to other cancers, treatment plans for SCC are based upon the likelihood that your tumor may spread or metastasize. Traditionally, this was estimated using only the presence or absence of risk factors. Traditional factors that indicate your tumor may be at a higher risk include: tumors that are large in size or appear in specific locations (i.e., ear, lip and temple); tumors that look “poorly differentiated” (disorganized) under the microscope; tumors that approach and invade nerves (perineural involvement); tumors that are found to be deep; during surgery, you have immunosuppression; tumors that are growing rapidly.
No. Only healthcare professionals (physician, physician assistants, or nurse practitioner) can order a test from Castle Biosciences. If you need help finding a healthcare professional who can order the test for you, please contact our customer service team at 866-788-9007 or email us..
Castle Biosciences operates clinical laboratories in Phoenix and Pittsburgh. The Company’s laboratories are College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified, reflecting the Company’s commitment to high-quality standards and excellence in patient care. Castle's laboratories are licensed to perform tests throughout the United States.
Castle Biosciences works with all insurance providers, including Medicare, commercial insurers, and the VA, to secure payment coverage for tests. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient Assistance Program with the belief that quality care should not depend on financial considerations.
Molecular diagnostic testing is a fast-growing field, so your healthcare professional may not know about all of the tests that are now available. If your healthcare professional is interested in more information, please ask them to contact us at 866-788-9007.
The DecisionDx-SCC genomic test measures the biological activity of specific genes in your tumor that tell how likely it is for your tumor to spread or metastasize. The DecisionDx-SCC test identifies the risk of squamous cell tumors spreading better than traditional measures alone. It is intended to be used in patients with an SCC diagnosis and the presence of one or more traditional risk factors.
Your healthcare provider can use your test results, in combination with other information and procedures, to personalize your treatment and follow-up care. For example, if your tumor is low (Class 1), routine treatment options may be a reasonable choice, avoiding unnecessary treatments and frequent follow-up unless they become necessary later. Conversely, if your test results identify your tumor as moderate or high biological risk (Class 2A or 2B) perhaps a more aggressive approach to treatment.
If you wish to have the DecisionDx-SCC test, please discuss it with your healthcare provider. Only a healthcare provider (physician, physician assistants, or nurse practitioner) can order this test.